Early immune activation profile in stage I hypertension and its predictive risk value in 5 years follow up

OBREGON S; CHULUYAN E; AQUINO J; INSERRA F; BOTTO F; KOTLIAR C

Paris

Congreso; 26th European Meeting of Hypertension; 2016

European Society of Hypertension

Objective: To describe immune basal profi le and its predictive value on the incidence of cardiovascular events and blood pressure evolution in hypertensive stage I subjects. Design and method: Patients with mild hypertension were recruited with at least 5 years from diagnosis. Exclusion criteria were: GFR > 60 ml/min/1.73 m2 (MDRD) microalbuminuria > 30 mg / 24 hs, previous CV events, autoimmune disease, use of imunomodulatory agents or corticosteroids. At entry and follow up offi ce and 24 hs ambulatory BP was measured; cell subpopulations were measured by fl ow cytometry in peripheral blood and direct cell count respectively, using T and dendritic cells monoclonal antibodies. End points were defined as the incidence of stroke, ischemic heart disease, new onset diabetes,cardiovascular and all-cause mortality, and number/doses of antihypertensivedrugs and BP. Results: 72 subjects were classifi ed in two groups: a) hypertensives, n:50 (24 women, 55.0 ± 9.0 years, 132 ± 6.4/80.3 ± 8.7 mmHg, number of antihypertensive drugs 2.0 ± 1.5.) and b) normotensive, n:22 (12 women, 53 ± 11 years). Median follow up: 5.4. ± 3.3 years. The distribution of immune markers in hypertensive was expressed as median x 106 cells/L (range): 650.40 CD4 + (272?980), CD8 + 110.37 (80?143), CD4 +/CD8 + 5.30 (2.50?9.90), CD25 + 86.90 (80.0?99.6), CD86 + (69.8?448.70), CD83 + (69.40?145). Compared to controls, HTs had a profi le with higher CD3 + CD4 + CD83 + CD86 + (< 0.001). At follow up, we found a direct association between the RR of events in the entire population (HT and NT) with higher baseline CD4 +, CD83 +, CD86 +, increased CD4 +/CD8 +, CD25 + lower ratio/CD4 + (